Patrys wins new Aussie patent for cancer antibody

Patrys (ASX:PAB) has secured a second Australian patent for clinical-stage anticancer antibody PAT-SM6, under development in multiple myeloma.

The Australian Patent Office has granted Patrys a patent covering “Novel glycosylated peptide target in neoplastic cells”, broadening the company’s intellectual property protection.

The claims in the patent cover the use of the PAT-SM6 antibody and binding fragments to treat various cancers including multiple myeloma.

Patrys has now secured a total of seven patents covering the PAT-SM6 family. The other patents have been granted jurisdictions including Europe, Japan and the US.

“This new patent goes a step further in protection for our lead clinical candidate PAT-SM6 until 2027,” Patrys CEO Marie Roskrow said.

“PAT-SM6 has already been granted orphan designation in both Europe and the US, so Patrys is in an excellent position to capitalise on the future returns of this novel antibody product.”

Earlier this month, Patrys announced that it will team up with Onyx Pharmaceuticals to test PAT-SM6 in combination with carfilzomib for multiple myeloma patients. The company also announced the award of a US patent covering another anticancer antibody in development, PAT-LM1.

Patrys (ASX:PAB) shares were trading 1.56% lower at $0.063 as of around 12.30 pm on Tuesday.